Influences of Bifid Triple Viable Capsules Plus Cetirizine on Gut Microbiota and Immune Function in Children with Eczema

Abstract

Objective Infantile eczema (IE), a common pediatric allergic skin disease caused by multiple inherent and external factors, is common in infants and young children, with skin lesions and itching as the main clinical manifestations. At present, its pathological mechanism has not been thoroughly clarified, but scholars believe that it is related to the joint action of various internal and external factors. This research aims to investigate the influences of bifid triple viable capsules plus cetirizine (CTZ) on gut microbiota (GMB) and immunity in children with eczema. Methods The complete clinical data of 162 cases of IE presented between July 2019 and July 2020 to the First Hospital of Shanxi Medical University were retrospectively analyzed. Children treated by CTZ alone were assigned to the control group (n = 81) and those by CTZ plus bifid triple viable capsules were included in the observation group (n = 81). Therapeutic efficacy, adverse reactions (ARs), disease recurrence, as well as changes in GMB, inflammatory factors (IFs) and immunoglobulins (Igs) were observed. Results The observation group was observed with a higher overall response rate and increased fecal Lactobacillus, Escherichia coli ( E. coli ) and Bifidobacterium counts after treatment versus the control group. After treatment, reduced IgG and IgM, as well as IFs, were found in both groups, with lower levels in the observation group. A lower incidence of ARs was determined in the observation group. Conclusion With high efficacy for the treatment of IE, bifid triple viable capsules plus CTZ can validly regulate the GMB of children, improve their immune function and clinical symptoms, and reduce the disease recurrence rate, which is worthy of clinical promotion.

Effect of Different Doses of Vitamin D on the Intestinal Flora of Babies with Eczema: An Experimental Study

“…The incidence rate of eczema in infants is high, especially in infancy [6]. Although the pathogenesis of infantile eczema has not been fully elucidated, many reports have indicated that the occurrence of infantile eczema is often related to the immature development of the immune system, the imperfect development of the intestinal barrier, family genetics, environmental factors (drugs, smoking environment), and the baby's diet [7]. Recent studies have suggested that the development of the gut microbiota is decisive to the proper function of the guts and the development of the immune system [8].…”

“…Therefore, the baby is routinely given a certain dose of Vit D (preventive dose 400 IU/d) until the age of two years [12]. Infantile eczema is often accompanied by immune dysfunction and dysbiosis of the intestinal florae [7]. Therefore, this study aimed to investigate if changing the dose of vitamin D can make the intestinal flora and immune function of eczema infants who usually adhere to Vit D 400 IU/d feeding return to normal levels.…”